In-vitro immunogenicity prediction [WEBINAR]

For more information, visit: https://www.miltenyibiotec.com/DE-en/... Success of biologic drug development is often tempered by antidrug antibodies that can lead to unwanted immune responses. A key for successful development of therapeutics is early immunogenicity prediction.
In vitro assays offer many benefits for early immunogenicity prediction and primary cells are a necessary component of such assays. Thorough planning with standardized and high quality cellular material can lead to more reliable results.

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.